🚀 VC round data is live in beta, check it out!
Septerna Valuation Multiples
Discover revenue and EBITDA valuation multiples for Septerna and similar public comparables like Neuren Pharma, Savara, Alvotech, Guilin Sanjin and more.
Septerna Overview
About Septerna
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Founded
2019
HQ
Employees
75
Website
Sectors
Financials (LTM)
EV
$778M
Septerna Financials
Septerna reported last 12-month revenue of $51M.
In the same LTM period, Septerna generated $51M in gross profit and had net loss of ($55M).
Revenue (LTM)
Septerna P&L
In the most recent fiscal year, Septerna reported revenue of $46M and EBITDA of ($79M).
Septerna expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $51M | XXX | $46M | XXX | XXX | XXX |
| Gross Profit | $51M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($79M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (172%) | XXX | XXX | XXX |
| EBIT Margin | (152%) | XXX | (156%) | XXX | XXX | XXX |
| Net Profit | ($55M) | XXX | ($49M) | XXX | XXX | XXX |
| Net Margin | (109%) | XXX | (106%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Septerna Stock Performance
Septerna has current market cap of $1B, and enterprise value of $778M.
Market Cap Evolution
Septerna's stock price is $27.44.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $778M | $1B | 0.0% | XXX | XXX | XXX | $-1.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSepterna Valuation Multiples
Septerna trades at 15.4x EV/Revenue multiple, and (9.8x) EV/EBITDA.
EV / Revenue (LTM)
Septerna Financial Valuation Multiples
As of March 18, 2026, Septerna has market cap of $1B and EV of $778M.
Equity research analysts estimate Septerna's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Septerna has a P/E ratio of (22.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $778M | XXX | $778M | XXX | XXX | XXX |
| EV/Revenue | 15.4x | XXX | 16.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (9.8x) | XXX | XXX | XXX |
| EV/EBIT | (10.1x) | XXX | (10.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 15.4x | XXX | — | XXX | XXX | XXX |
| P/E | (22.2x) | XXX | (25.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Septerna Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Septerna Margins & Growth Rates
Septerna's revenue in the last 12 month grew by 33%.
Septerna's revenue per employee in the last FY averaged $0.7M.
Septerna Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (172%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 61% | XXX | 64% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 206% | XXX | 212% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 276% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Septerna Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neuren Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Savara | XXX | XXX | XXX | XXX | XXX | XXX |
| Alvotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| Inventiva | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Septerna M&A Activity
Septerna acquired XXX companies to date.
Last acquisition by Septerna was on XXXXXXXX, XXXXX. Septerna acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Septerna
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSepterna Investment Activity
Septerna invested in XXX companies to date.
Septerna made its latest investment on XXXXXXXX, XXXXX. Septerna invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Septerna
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Septerna
| When was Septerna founded? | Septerna was founded in 2019. |
| Where is Septerna headquartered? | Septerna is headquartered in United States. |
| How many employees does Septerna have? | As of today, Septerna has over 75 employees. |
| Who is the CEO of Septerna? | Septerna's CEO is Jeffrey T. Finer. |
| Is Septerna publicly listed? | Yes, Septerna is a public company listed on Nasdaq. |
| What is the stock symbol of Septerna? | Septerna trades under SEPN ticker. |
| When did Septerna go public? | Septerna went public in 2024. |
| Who are competitors of Septerna? | Septerna main competitors are Neuren Pharma, Savara, Alvotech, Guilin Sanjin. |
| What is the current market cap of Septerna? | Septerna's current market cap is $1B. |
| What is the current revenue of Septerna? | Septerna's last 12 months revenue is $51M. |
| What is the current revenue growth of Septerna? | Septerna revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Septerna? | Current revenue multiple of Septerna is 15.4x. |
| Is Septerna profitable? | No, Septerna is not profitable. |
| What is the current net income of Septerna? | Septerna's last 12 months net income is ($55M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.